Ardent Health Partners, LLC
NYSE:ARDTMedical - Care Facilities
-$0.14 today
- Market cap
- $2.03B
- Beta
- 0.84
- P/E (TTM)
- 9.4
- EPS (TTM)
- $0.95
Volume 7.27M
Average 0.45M
ARDT Cost of Revenue
Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.
Ardent Health Partners, LLCNYSE: ARDT
Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026
Cost of revenue growth accelerates
Q1 FY2026 cost of revenue of $1.36B rose 423.8% year over year, ahead of the +127.0% change in trailing-twelve-month cost of revenue. Sequentially, it rose 46.0% from the prior quarter. Over 3 fiscal years it compounded at -45.4% a year.
Context
- Cost of revenue amounted to 2.5% of revenue in FY2025, down 14.9 pp from a year earlier.
- Cost of revenue increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +423.8% holds above the trailing-twelve-month pace of +127.0%.
Sources:Income StatementText generated from reported figures; not investment advice.
Cost of Revenue history
USD · from the income statement
- Latest · FY2025
- 155.7M USD
- Year-over-year change
- -84.9%
- 4-year CAGR
- -36.0%
| Period | Period end | Cost of Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 155.7M | -84.9% |
| FY2024 | 2024-12-31 | 1.03B | +633.5% |
| FY2023 | 2023-12-31 | 140.84M | -85.3% |
| FY2022 | 2022-12-31 | 955.17M | +3.0% |
| FY2021 | 2021-12-31 | 927.33M | — |
Cost of Revenue vs competitors
How ARDT compares with its peers on the latest reported figures
- ARDT's LTM Mar 2026 cost of revenue of $3.23B is the 2nd highest of the 11 companies compared; the peer median is $1.67B.
- Its year-over-year change of +127.0% is the 2nd highest of 11, against a peer median of +18.9%.
- Cost of revenue amounts to 50.3% of revenue for ARDT, versus a peer median of 68.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $4.93B | +28.0% | -4.9% | 89.4% | |
ARDTArdent Health Partners, LLC | LTM Mar 2026 | $3.23B | +127.0% | -45.4% | 50.3% |
| LTM Mar 2026 | $3.2B | +61.8% | +45.1% | 90.7% | |
| LTM Sep 2026 | $2.52B | +11.2% | +3.6% | 85.5% | |
| LTM Sep 2026 | $2.14B | +252.6% | +200.9% | 62.7% | |
| LTM Oct 2026 | $1.82B | +19.3% | +9.7% | 67.9% | |
| LTM Sep 2026 | $1.53B | +7.1% | -1.4% | 78.0% | |
| LTM Sep 2026 | $1.08B | +16.9% | +10.3% | 68.0% | |
| LTM Jun 2026 | $1.05B | +18.5% | +15.7% | 66.4% | |
| LTM Jun 2026 | $998.65M | +16.3% | +13.8% | 67.6% | |
| LTM Sep 2026 | $6.07M | +40.5% | — | 3.3% | |
| Peer median (excluding ARDT) | $1.67B | +18.9% | +10.3% | 68.0% | |
Competitors are the stored peer set for ARDT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 4.87B | 5.13B | 5.41B | 5.97B | 6.32B |
| Cost of Revenue | 927.33M | 955.17M | 140.84M | 1.03B | 155.7M |
| Gross Profit | 3.94B | 4.17B | 5.27B | 4.93B | 6.17B |
| Gross Margin | 81.0% | 81.4% | 97.4% | 82.7% | 97.5% |
| Research & Development | 0 | 0 | 0 | 0 | 0 |
| Selling, General & Admin | 3.13B | 3.37B | 3.62B | 3.88B | 1.19B |
| Operating Expenses | 3.51B | 3.96B | 5.04B | 4.53B | 5.84B |
| Depreciation & Amortization | 137.2M | 138.17M | 140.84M | 146.29M | 155.7M |
| EBITDA | 526.93M | 531.7M | 350M | 574.93M | 497.26M |
| EBITDA Margin | 10.8% | 10.4% | 6.5% | 9.6% | 7.9% |
| Operating Income | 436.56M | 217.03M | 229.5M | 405.76M | 325.58M |
| Operating Margin | 9.0% | 4.2% | 4.2% | 6.8% | 5.1% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 93.83M | 82.05M | 65.43M | 65.58M | 55.2M |
| Other Income / Expenses | (140.68M) | 94.45M | (77.89M) | (42.7M) | (39.23M) |
| Income Before Tax | 295.89M | 311.48M | 151.61M | 363.06M | 286.36M |
| Pre-Tax Margin | 6.1% | 6.1% | 2.8% | 6.1% | 4.5% |
| Income Tax Expense | 51.31M | 46.11M | 22.64M | 63.35M | 56.22M |
| Net Income | 154.26M | 188.91M | 50.29M | 210.34M | 135.81M |
| Net Margin | 3.2% | 3.7% | 0.9% | 3.5% | 2.1% |
| EPS (Basic) | 1.08 | 1.32 | 0.35 | 1.59 | 0.96 |
| EPS (Diluted) | 1.08 | 1.32 | 0.35 | 1.58 | 0.96 |
| Weighted Avg Shares | 143.26M | 143.26M | 143.26M | 132.44M | 140.76M |
| Weighted Avg Shares (Diluted) | 143.26M | 143.26M | 143.26M | 132.75M | 141.45M |
Ardent Health Partners, LLC
NYSE:ARDT
Intrinsic Alpha fair value
Locked
Current Price
$14.40
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.